A5022320757- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Radiopharmaceutical Chemistry and Applications
- Esophageal Cancer Research and Treatment
- Urological Disorders and Treatments
- Renal and related cancers
- Urologic and reproductive health conditions
- Cancer, Lipids, and Metabolism
- Advanced Radiotherapy Techniques
- Inflammatory Biomarkers in Disease Prognosis
- Minimally Invasive Surgical Techniques
- Kidney Stones and Urolithiasis Treatments
- Hormonal and reproductive studies
- Multiple and Secondary Primary Cancers
- Cancer Genomics and Diagnostics
- Pituitary Gland Disorders and Treatments
- Multiple Myeloma Research and Treatments
- Cancer, Hypoxia, and Metabolism
- Statistical Methods in Clinical Trials
- Venous Thromboembolism Diagnosis and Management
- Tuberous Sclerosis Complex Research
Jikei University Kashiwa hospital
2019-2025
Jikei University School of Medicine
2018-2025
John Wiley & Sons (United States)
2018
Hudson Institute
2018
Abstract Background Despite its demonstrated efficacy in prolonging overall survival (OS) and delaying skeletal-related events the ALSYMPCA trial, optimal timing of radium-223 initiation remains unclear. This study investigated factors influencing treatment outcomes, including completion rates survival. Methods retrospective, multi-institutional included 164 patients with metastatic castration-resistant prostate cancer (CRPC) who received therapy. The primary endpoint was OS following...
Background A multicenter database was utilized to examine the current treatment landscape and clinical outcomes among patients with metastatic hormone‐sensitive prostate cancer (mHSPC) following approval of upfront androgen receptor signaling inhibitors (ARSIs). Methods We retrospectively analyzed mHSPC who commenced between February 2018 June 2023. The Kaplan–Meier method used assess oncological outcomes, including time castration‐resistant (CRPC), progression‐free survival 2 (PFS2,...
To assess the clinical significance of repeat transurethral resection (reTUR) and surgical margin status after en bloc bladder tumour (ERBT) for pathological T1 (pT1) cancer.We retrospectively analysed record 106 patients with pT1 high-grade cancer who underwent ERBT between April 2013 February 2021 at multiple institutions. All specimens were reviewed by a genitourinary pathologist. The primary outcome measures recurrence-free survival (RFS) progression-free (PFS) those without reTUR. We...
Abstract Background The JAVELIN Bladder 100 trial demonstrated improved overall survival (OS) with maintenance avelumab in patients locally advanced or metastatic urothelial carcinoma UC (la/mUC) who achieved disease control following first-line platinum-based chemotherapy (1 L-PBC). However, real-world data on eligibility, utilization, and outcomes of therapy remain limited. Methods This retrospective study included la/mUC received 1 L-PBC. Eligibility for was determined based the best...
Background/Aim: The lung immune prognostic index (LIPI), which is determined by assessing the derived neutrophil-to-lymphocyte ratio in conjunction with level of lactate dehydrogenase, predicts outcomes various cancers. Its utility as a preoperative biomarker upper tract urothelial carcinoma (UTUC) patients remains unexplored. Patients and Methods: This retrospective study UTUC who underwent radical nephroureterectomy. were stratified into favorable, intermediate, poor LIPI groups....
ABSTRACT Introduction Prostate‐specific antigen (PSA) kinetics serve as valuable surrogate markers for estimating survival outcomes in metastatic hormone‐sensitive prostate cancer (mHSPC) treated with androgen receptor pathway inhibitors (ARPI). While both the PSA response rate and absolute value are typically assessed, determining which marker holds greater significance real‐world clinical settings is a critical question. In this study, we compare 3 months after initiation of doublet ARPI...
Abstract Background Despite advancements in treatment options for metastatic urothelial carcinoma (mUC), therapeutic choices remain limited patients with disease refractory to platinum-based chemotherapy (PBC) and immune checkpoint inhibitors (ICIs). Enfortumab vedotin (EV) has demonstrated significant efficacy later lines of therapy mUC; however, its organ-specific responses uncertain. Methods We conducted a retrospective study 69 mUC who received EV following PBC ICIs. Efficacy was...
ABSTRACT Background Few studies have provided a comprehensive analysis of sequential treatment strategies for locally advanced and metastatic urothelial carcinoma (la/mUC). This study assessed patterns, prognostic factors, optimal sequencing in patients receiving first‐line platinum‐based chemotherapy (1 L‐PBC). Methods retrospective, multicenter analyzed 212 la/mUC who initiated 1 L‐PBC. Treatment sequences were categorized based on the therapy, including immune‐oncology (IO) drug...
Aims En‐bloc transurethral resection (TUR) of bladder tumour (ERBT) is designed to provide more accurate pathological diagnosis specimens than conventional TUR (cTURBT). Some studies have reported that T1 cancer substage could be a prognostic factor in assessing progression, but such substaging has not been widely adopted because problems with using cTURBT specimens. The aim this study was evaluate the possible advantages en‐bloc following assessment by panel 10 pathologists. Methods and...
No AccessJournal of UrologyAdult Urology1 Jun 2021Vertical Lamina Propria Invasion Diagnosed by En Bloc Transurethral Resection is a Significant Predictor Progression for pT1 Bladder Cancer Takafumi Yanagisawa, Miki, Takashi Yorozu, Kosuke Iwatani, Koki Obayashi, Shun Sato, Takahiro Kimura, Hiroyuki Takahashi, and Shin Egawa YanagisawaTakafumi Yanagisawa *Correspondence: Department Urology, Jikei University Kashiwa Hospital, 163-1 Kashiwashita, Kashiwa, Chiba 277-8567Japan telephone:...